Latest Regulatory Filings News

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

ASX Compliance has formally questioned Rewardle Holdings Limited over delayed disclosures, financial inconsistencies, and governance concerns tied to its investments in Pepper Leaf, Beanhunter, and CloudHolter.

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.

Hydralyte USA has placed 39.5 million shortfall shares at $0.01 each, boosting total funds raised under its recent Rights Issue to nearly $559,000. The move strengthens the company’s capital position amid ongoing growth efforts.

Medallion Metals reports standout gold and copper assays from Harbour View infill drilling, reinforcing resource confidence ahead of a July update and advancing its strategic Forrestania acquisition.

Lincoln Minerals has identified multiple high-priority drill targets at its Minbrie Copper-Base Metals Project in South Australia, with drilling approvals advancing for a campaign planned in the second half of 2025.

Capricorn Metals capped FY25 with a strong Q4 at Karlawinda, delivering gold production at the upper guidance range while pushing forward major development milestones.

Aguia Resources has successfully closed its Share Purchase Plan, raising approximately $649,200 through the issuance of over 18 million new shares. This capital injection supports the company’s phosphate and gold projects in Brazil and Colombia.

Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.